S
Stergios Zacharoulis
Researcher at Cornell University
Publications - 21
Citations - 3081
Stergios Zacharoulis is an academic researcher from Cornell University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 2810 citations. Previous affiliations of Stergios Zacharoulis include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Rosandra N. Kaplan,Rebecca D. Riba,Stergios Zacharoulis,Anna H. Bramley,Loic Vincent,Carla Costa,Daniel D. MacDonald,David K. Jin,Koji Shido,Scott A. Kerns,Zhenping Zhu,Daniel J. Hicklin,Yan Wu,Jeffrey L. Port,Nasser K. Altorki,Elisa Port,Davide Ruggero,Sergey V. Shmelkov,Kristian K. Jensen,Shahin Rafii,David Lyden +20 more
TL;DR: A requirement for VEGFR1+ haematopoietic progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1) home to tumour-specific pre-metastatic sites and form cellular clusters before the arrival of tumour cells is demonstrated.
Journal ArticleDOI
Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia.
James B. Bussel,Stergios Zacharoulis,Kim Kramer,Janice G. McFarland,Joanne Pauliny,Cécile Kaplan +5 more
TL;DR: This study was undertaken to compare the outcome of cases of AIT to cases of neonatal thrombocytopenia shown not to be AIT and to identify clinical features that would facilitate the diagnosis.
Journal ArticleDOI
p130Rb2 and p27kip1 cooperate to control mobilization of angiogenic progenitors from the bone marrow.
Anxo Vidal,Anxo Vidal,Stergios Zacharoulis,Stergios Zacharoulis,Wenjun Guo,David R. Shaffer,Filippo G Giancotti,Anna H. Bramley,Carmen de la Hoz,Kristian Jensen,Daniel Kato,Daniel D. MacDonald,Joseph Knowles,Nancy Yeh,Lawrence A. Frohman,Shahin Rafii,David Lyden,Andrew Koff +17 more
TL;DR: It is reported that mice lacking the cell cycle inhibitors p130 and p27 show defects in tumor neoangiogenesis, both in xenografts and spontaneously arising tumors, and it is suggested that cell expansion and mobilization from the bone marrow of angiogenic precursors are separable events.
Journal ArticleDOI
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Eleonora F. Spinazzi,Michael Argenziano,Pavan S. Upadhyayula,Matei A. Banu,Justin A. Neira,Dominique M. Higgins,Peter B. Wu,Brianna Pereira,Aayushi Mahajan,Nelson Humala,Osama Al-Dalahmah,Wenting Zhao,Akshay V. Save,Brian J A Gill,Deborah Boyett,Tamara Marie,J. Furnari,Tejaswi Sudhakar,Sylwia A. Stopka,Michael S. Regan,Vanessa V. Catania,Laura Good,Stergios Zacharoulis,Meenu Behl,Petros Petridis,Sachin Jambawalikar,Akiva Mintz,Angela Lignelli,Nathalie Y. R. Agar,Peter J. Sims,Mary Welch,Andrew B. Lassman,Fabio M. Iwamoto,Randy S. D'Amico,Jack Grinband,Peter Canoll,Jeffrey N. Bruce +36 more
TL;DR: It is shown that chronic CED of topotecan is a potentially safe and active therapy for recurrent glioblastoma and could be applicable for other anti-glioma drugs or other CNS diseases.
Journal ArticleDOI
DDEL-07. A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas (DMGs)
Stergios Zacharoulis,Luca Szalontay,Travis S. CreveCoeur,Justin A. Neira,Dominique M. Higgins,Zachary K. Englander,Eleonora F. Spinazzi,Chankrit Sethi,Peter Canoll,James Garvin,Rebecca J. Zylber,Steve Damment,Dmitry Zamoryakhin,Alexis B. Maddocks,Neil A. Feldstein,Jeffrey N. Bruce +15 more
TL;DR: Using MTX110, the safety and feasibility of repeated drug infusion by CED in DMG patients was demonstrated and all but one patient had adequate tumor coverage as measured by co-infused gadolinium on MRI.